Diabetes, over time, triggers a cascade of complications throughout the body. Among these, diabetic kidney disease (DKD), a condition where the kidneys progressively lose function due to diabetes, stands out as a particularly grave threat. In fact, diabetes is the leading cause of end-stage renal disease (ESRD), a life-threatening condition where kidney function drops below 10% of the normal, often necessitating dialysis. The sobering reality is underscored by the 'End-Stage Renal Disease Fact Sheet 2024' published by the Korean Society of Nephrology Registry Committee, which reveals that a staggering 48% of all cases requiring dialysis are attributed to diabetes.
The kidneys, vital organs responsible for filtering waste products from the blood, regulating blood pressure, and secreting essential hormones, are indispensable for maintaining overall health. When these crucial organs sustain damage for more than three months, the condition is classified as chronic kidney disease (CKD). The insidious nature of CKD lies in its often silent progression, with noticeable symptoms typically absent in the early stages, making timely detection a significant challenge. Consequently, it is paramount for individuals with diabetes to undergo annual screenings, including an albuminuria test and a glomerular filtration rate (GFR) test, to diligently monitor their kidney health.
Albumin, a primary protein in the human body, is not usually detected in significant amounts in urine under normal circumstances. For a healthy adult, the daily urinary albumin excretion should remain below 30 milligrams. However, as kidney function deteriorates, a condition known as albuminuria occurs, characterized by the excessive leakage of albumin into the urine. This protein spillage serves as an early indicator of kidney damage and warrants prompt medical attention.
Each kidney houses approximately one million glomeruli, the primary filtering units. These intricate structures, composed of tangled capillaries, diligently filter waste products from the bloodstream. The glomerular filtration rate (GFR) quantifies the volume of blood filtered by the glomeruli per minute. This rate can be estimated through blood tests measuring creatinine levels, a waste product. A normal GFR typically ranges from 90 to 120 milliliters per minute. Based on this metric, kidney function is categorized into five stages. Alarmingly, when the GFR falls below 15 ml/min (stage 5), the kidneys can no longer sustain life independently, necessitating renal replacement therapy such as dialysis or kidney transplantation.
Effective management of blood glucose levels through medication is crucial in slowing the progression of DKD. Persistent hyperglycemia (high blood sugar) in diabetic patients damages the delicate microvasculature within the kidneys, impairing their filtering capacity. Glycated hemoglobin (HbA1c) levels, which reflect average blood sugar control over the preceding two to three months, are commonly used to guide diabetes management. The general target for HbA1c in most diabetic patients is below 6.5%. However, individualized treatment strategies are often employed, particularly for elderly patients, where a slightly higher HbA1c target might be set to mitigate the risk of hypoglycemia (low blood sugar).
Beyond glucose control, meticulous management of hypertension (high blood pressure) is equally vital in the context of DKD. Hypertension acts as an accelerating factor in kidney disease progression, and proactive blood pressure control has been shown to significantly benefit the treatment of DKD. Angiotensin-converting enzyme inhibitors (ACEis) and angiotensin II receptor blockers (ARBs), classes of antihypertensive medications, have demonstrated efficacy in reducing albuminuria and slowing the advancement of kidney disease. These agents are often the first-line treatment for diabetic patients with hypertension and can even be considered in the absence of high blood pressure if albuminuria is present.
Professor Jin-joo Cha, a nephrologist at Korea University Ansan Hospital, highlights the evolving landscape of DKD management, stating, "Recent approaches extend beyond mere blood glucose and blood pressure control to encompass multifaceted strategies aimed at kidney protection and prevention of cardiovascular complications." She emphasizes the role of sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of glucose-lowering drugs that have shown promise in slowing disease progression and reducing cardiovascular risk in patients with DKD. Furthermore, glucagon-like peptide-1 (GLP-1) receptor agonists, which lower blood sugar while also offering cardioprotective and renoprotective benefits, are increasingly being used as adjunctive therapies for kidney protection.
Non-steroidal mineralocorticoid receptor antagonists also offer a therapeutic avenue by reducing inflammation and fibrosis in the kidneys, thereby hindering disease progression. However, these medications can be associated with side effects such as urinary tract infections and gastrointestinal disturbances, necessitating close consultation with a nephrologist to tailor the treatment plan based on individual kidney status and ensure diligent ongoing management.
Preventive measures play a crucial role in mitigating the risk and progression of DKD. Smoking cessation and regular moderate exercise are strongly recommended. For individuals who are overweight or obese, weight loss through exercise and dietary modifications to achieve and maintain a healthy weight is essential. Dietary sodium intake should be limited, and individuals with diabetes must engage in regular consultations with their healthcare providers to ensure meticulous management of both blood glucose and blood pressure levels.
The alarming statistic that nearly half of all new cases of ESRD are attributable to diabetes underscores the critical need for heightened awareness, proactive screening, and comprehensive management strategies for DKD. The silent nature of early kidney damage necessitates vigilant monitoring, particularly in the diabetic population. By embracing regular check-ups, adhering to prescribed medications, adopting healthy lifestyle choices, and engaging in open communication with healthcare professionals, individuals with diabetes can significantly reduce their risk of progressing to life-threatening kidney failure and safeguard their long-term health. The fight against this silent threat requires a concerted effort from patients, healthcare providers, and the broader community to prioritize early detection and proactive intervention.
[Copyright (c) Global Economic Times. All Rights Reserved.]
